Known central nervous system (CNS) metastases. Subjects with any active autoimmune disease or history of autoimmune disease. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) > NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; Active infection or an unexplained fever > 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); History of Interstitial Pneumonia or active non-infectious pneumonitis. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.